Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain

Anita Elaine Weidmann, Scott Cunningham, Gwen Gray, Denise Hansford, James McLay, John Broom, Derek Stewart

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives of the study To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.

Original languageEnglish
Pages (from-to)627-633
Number of pages7
JournalInternational Journal of Clinical Pharmacy
Volume33
Issue number4
DOIs
Publication statusPublished - Aug 2011

Keywords

  • Community pharmacist
  • Great Britain
  • Obesity
  • Orlistat
  • OTC
  • Over-the-counter medicines
  • Pharmacist experience
  • Pharmacist views
  • Weight-loss
  • Management
  • Simvastatin
  • Patient
  • Misuse
  • Trial

Cite this

Over-the-counter orlistat : early experiences, views and attitudes of community pharmacists in Great Britain. / Weidmann, Anita Elaine; Cunningham, Scott; Gray, Gwen; Hansford, Denise; McLay, James; Broom, John; Stewart, Derek.

In: International Journal of Clinical Pharmacy, Vol. 33, No. 4, 08.2011, p. 627-633.

Research output: Contribution to journalArticle

Weidmann, Anita Elaine ; Cunningham, Scott ; Gray, Gwen ; Hansford, Denise ; McLay, James ; Broom, John ; Stewart, Derek. / Over-the-counter orlistat : early experiences, views and attitudes of community pharmacists in Great Britain. In: International Journal of Clinical Pharmacy. 2011 ; Vol. 33, No. 4. pp. 627-633.
@article{c5ff93f2cdb84c548811d644971d467d,
title = "Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain",
abstract = "Objectives of the study To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81{\%}) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4{\%} (n = 4,026) of pharmacists surveyed. Just over half (51.9{\%}, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1{\%} (n = 203) reporting frequent (5.1{\%}) or very frequent supply in the same time frame. Two thirds (66.5{\%}, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92{\%} (n = 3,712) felt confident in their ability to supply this product. Over half (57.9{\%}, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8{\%} (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.",
keywords = "Community pharmacist, Great Britain, Obesity, Orlistat, OTC, Over-the-counter medicines, Pharmacist experience, Pharmacist views, Weight-loss, Management, Simvastatin, Patient , Misuse, Trial",
author = "Weidmann, {Anita Elaine} and Scott Cunningham and Gwen Gray and Denise Hansford and James McLay and John Broom and Derek Stewart",
year = "2011",
month = "8",
doi = "10.1007/s11096-011-9516-z",
language = "English",
volume = "33",
pages = "627--633",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Over-the-counter orlistat

T2 - early experiences, views and attitudes of community pharmacists in Great Britain

AU - Weidmann, Anita Elaine

AU - Cunningham, Scott

AU - Gray, Gwen

AU - Hansford, Denise

AU - McLay, James

AU - Broom, John

AU - Stewart, Derek

PY - 2011/8

Y1 - 2011/8

N2 - Objectives of the study To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.

AB - Objectives of the study To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.

KW - Community pharmacist

KW - Great Britain

KW - Obesity

KW - Orlistat

KW - OTC

KW - Over-the-counter medicines

KW - Pharmacist experience

KW - Pharmacist views

KW - Weight-loss

KW - Management

KW - Simvastatin

KW - Patient

KW - Misuse

KW - Trial

U2 - 10.1007/s11096-011-9516-z

DO - 10.1007/s11096-011-9516-z

M3 - Article

VL - 33

SP - 627

EP - 633

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 4

ER -